← All trials
NCT06523959
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2024
- Primary completion
- Sep 30, 2028
- Completion date
- Dec 31, 2028
- First posted
- Jul 29, 2024
- Last posted
- Jul 29, 2024
- Enrollment
- 5436
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SherbrookeLead sponsor
- University of TurkuCollaborator
- McMaster UniversityCollaborator
- University of HelsinkiCollaborator
- University of OuluCollaborator
- University of HelsinkiCollaborator
- University of SherbrookeSponsor investigator
- University of LondonCollaborator
- University of TampereCollaborator
- Government of FinlandCollaborator
- Tabriz Medical UniversityCollaborator
- Albany Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.